MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13RALPHA1)
    2.
    发明申请
    MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13RALPHA1) 有权
    白细胞介素-1受体ALPHA 1(IL-13RALPHA1)的单克隆抗体

    公开(公告)号:US20110020363A1

    公开(公告)日:2011-01-27

    申请号:US12828589

    申请日:2010-07-01

    摘要: The present invention relates generally to antibodies that bind to the Interleukin-13 receptor.alpha.1 chain (IL-13R.alpha.1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R.alpha.1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R.alpha.1/ligand interaction is also provided.

    摘要翻译: 本发明一般涉及结合白细胞介素-13受体α1链(IL-13Rα1)并通过IL-13和/或IL-4拮抗IL-13受体介导的信号传导的抗体。 更具体地说,本发明为哺乳动物,特别是IL-13R.α提供人源化或人抗体。 这些抗体在治疗或预防IL-13和/或IL-4介导的疾病或病症中具有应用。 本发明进一步考虑通过施用受试者抗体调节IL-13和/或IL-4介导的疾病或病症的方法。 本发明还提供了可用于鉴定通过IL-13受体复合物调节IL-13和/或IL-4信号传导的抗体或其它试剂的测定系统。 因此,还提供了筛选IL-13R.alpha.1 /配体相互作用的调节剂的方法。